Literature DB >> 15187199

Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients.

Salvatore di Paolo1, Annalisa Teutonico, Giovanni Stallone, Barbara Infante, Antonio Schena, Giuseppe Grandaliano, Michele Battaglia, Pasquale Ditonno, Paolo F Schena.   

Abstract

BACKGROUND: Cyclosporin (CsA) level obtained 2 h after the morning dose (C(2)) has been shown to accurately predict total CsA exposure and acute rejection (AR) risk, whereas conventional trough levels (C(0)) do not. The impact of C(2) monitoring on long-term kidney graft function, independent from AR risk, is still unclear, however, and it was assessed in the present study.
METHODS: We enrolled 39 CsA-treated renal transplant recipients and used 1 year graft function and histological structure as surrogate markers of graft outcome. CsA dose was adjusted according to C(2) levels.
RESULTS: In the first 7 days after grafting, 40-51% of patients failed to reach target C(2) levels; nevertheless, at 1 year the incidence of AR was only 2.5% and graft and patient survival was 100%. The decrease of serum creatinine (12-6 months) was associated with significantly higher C(2) levels over time (P = 0.0003) and lower intrapatient variability of CsA relative absorption (CV) (P = 0.0006). One year graft biopsy showed chronic tubulointerstitial lesions in 54.5% of patients. Both C(2) mean levels and the percentage CV independently predicted the severity of chronic histological lesions (R = 0.69, P<0.0001).
CONCLUSIONS: Higher C(2) levels, within the proposed target range values, seem to be associated with better renal function and structure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187199     DOI: 10.1093/ndt/gfh344

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

Review 1.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

2.  Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants.

Authors:  Anja Gäckler; Sebastian Dolff; Hana Rohn; Johannes Korth; Benjamin Wilde; Ute Eisenberger; Anna Mitchell; Andreas Kribben; Oliver Witzke
Journal:  BMC Nephrol       Date:  2019-05-14       Impact factor: 2.388

3.  Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety.

Authors:  Xiaojuan Yu; Lin Ruan; Zhen Qu; Zhao Cui; Yimiao Zhang; Xin Wang; Liqiang Meng; Xiaojing Liu; Fang Wang; Ying Zhang; Gang Liu; Li Yang
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.